With key patents set to lapse at the end of the decade, biosimilar sponsors targeting Merck & Co’s Keytruda (pembrolizumab) intravenous injectable will be watching with a keen eye early in the new year as the originator targets a Phase III readout for a proposed subcutaneous version of its PD-1 inhibitor to treat forms of cancer.
Merck hopes to have Phase III data for a subcutaneous Keytruda formulation available in February 2023, providing a potential bulwark for its $20bn Keytruda giant that will lose protection in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?